Quarterly report pursuant to Section 13 or 15(d)

Segment Information

v2.4.0.6
Segment Information
9 Months Ended
Mar. 31, 2013
Segment Information

I. Segment Information:

The Company has two reportable segments based on the nature of products (biotechnology and hematology). Following is financial information relating to the Company’s reportable segments (in thousands):

 

      Quarter Ended
March 31,
    Nine Months Ended
March 31,
 
   2013     2012     2013     2012  

External sales

        

Biotechnology

   $ 75,285      $ 78,180      $ 214,416      $ 220,291   

Hematology

     5,707        5,441        16,684        15,588   
  

 

 

   

 

 

   

 

 

   

 

 

 

Consolidated net sales

   $ 80,992      $ 83,621      $ 231,100      $ 235,879   
  

 

 

   

 

 

   

 

 

   

 

 

 

Earnings before income taxes

        

Biotechnology

   $ 43,246      $ 45,442      $ 117,123      $ 123,304   

Hematology

     2,247        2,037        6,498        5,636   
  

 

 

   

 

 

   

 

 

   

 

 

 

Segment earnings before income taxes

     45,493        47,479        123,621        128,940   

Unallocated corporate expenses and equity method investee losses

     (1,027     (4,274     (3,723     (7,362
  

 

 

   

 

 

   

 

 

   

 

 

 

Consolidated earnings before income taxes

   $ 44,466      $ 43,205      $ 119,898      $ 121,578